Market News / Story
Cerenome Launches CNSide® CSF Molecular Profile Tests
GlobeNewswire ·
GlobeNewswire reports: New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026: CNSide® CSF…